Major Histocompatibility Complex I and II Expression and Lymphocytic Subtypes in Muscle of Horses with Immune-Mediated Myositis.
- Journal Article
- B cells
- Clinical Pathology
- Disease Etiology
- Equine Diseases
- Equine Health
- Horses
- Immune Response
- Immune System
- Immunohistochemistry
- Immunology
- Inflammatory Response
- Lymphocytes
- Major Histocompatibility Complex (MHC)
- Muscle
- Polysaccharide Storage Myopathy
- T Cells
- Veterinary Medicine
- Veterinary Research
- White Blood Cells
Summary
The research examines the expression levels of the Major Histocompatibility Complex (MHC) I and II in the muscle tissues of horses suffering from immune-mediated myositis (IMM), a condition where the body’s immune system mistakenly attacks healthy muscle tissue. The study also investigates any potential correlation between MHC expression, specific types of lymphocytes and the muscle protective protein, dysferlin.
Research Objective
The research has a threefold objective.
- First, it aims to determine if sarcolemmal MHC, a type of protein usually found on cell surfaces, is expressed in horses experiencing an active IMM episode.
- Second, the researchers wanted to check whether MHC expression is associated with a particular subtype of lymphocytes, a type of immune cell.
- Finally, the research seeks to ascertain if dysferlin, a muscle-protective protein, is expressed in IMM cases.
Methods
The study comprised of 21 IMM horses from Quarter Horse-related breeds, as well as 9 control horses (3 healthy, 3 with pasture myopathy, and 3 with polysaccharide storage myopathy [PSSM]). The researchers performed immunohistochemical staining on the archived muscle samples of these horses to determine the presence and levels of MHC I, II, and the lymphocyte subtypes CD4+, CD8+, and CD20+. Immunofluorescent staining was also done for proteins dysferlin, dystrophin, and a-sarcoglycan.
Findings
The researchers detected the expression of Sarcolemmal MHC I and II in the majority (17 out of 21 and 15 out of 21, respectively) of the IMM horses and in specific muscle fibers of PSSM horses, though such expressions weren’t found in healthy or pasture myopathy control horses. The lymphocyte subtypes were present in almost all IMM muscles, with CD4+ being predominant in 10 out of 21 cases, and CD8+ in 6 out of 21 cases. Meanwhile, the staining for dysferlin, dystrophin, and a-sarcoglycan was noted to be similar in both IMM cases and control horses.
Conclusions
The research concluded that there is no link between the deficiency of muscle-protective proteins dysferlin, dystrophin, and a-sarcoglycan with IMM. The presence of Sarcolemmal MHC I and II expression in muscle fibers of IMM horses, along with lymphocytic infiltration, supports the understanding that IMM is caused by an immune response. The expression of MHC was also found in specific muscle fibers of PSSM horses, even without noticeable lymphocytic infiltrates.
Cite This Article
Publication
Researcher Affiliations
- Department of Veterinary Population Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN.
- Department of Population Health and Reproduction, University of California-Davis, Davis, CA.
- Department of Veterinary Population Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN.
- Department of Veterinary Population Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN.
- Department of Pathology, University of California, San Diego, La Jolla, CA.
- Department of Pathology, University of California, San Diego, La Jolla, CA.
- Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, MI.
MeSH Terms
- Animals
- Gene Expression Regulation
- Horse Diseases / metabolism
- Horse Diseases / pathology
- Horses
- Lymphocyte Subsets
- Major Histocompatibility Complex / genetics
- Major Histocompatibility Complex / physiology
- Muscle, Skeletal / cytology
- Muscle, Skeletal / metabolism
- Muscle, Skeletal / pathology
- Myositis / immunology
- Myositis / pathology
- Myositis / veterinary
Grant Funding
- K01 OD015134 / NIH HHS
- L40 TR001136 / NCATS NIH HHS
References
- Lewis SS, Valberg SJ, Nielsen IL. Suspected immune-mediated myositis in horses.. J Vet Intern Med 2007 May-Jun;21(3):495-503.
- Pumarola M, Moore PF, Shelton GD. Canine inflammatory myopathy: analysis of cellular infiltrates.. Muscle Nerve 2004 Jun;29(6):782-9.
- Evans J, Levesque D, Shelton GD. Canine inflammatory myopathies: a clinicopathologic review of 200 cases.. J Vet Intern Med 2004 Sep-Oct;18(5):679-91.
- Hewer E, Goebel HH. Myopathology of non-infectious inflammatory myopathies - the current status.. Pathol Res Pract 2008;204(9):609-23.
- Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients.. Neurology 2001 Dec 11;57(11):2136-8.
- Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, Morandi L, Mora M, Cornelio F, Mantegazza R. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study.. J Neuroimmunol 2003 Sep;142(1-2):130-6.
- Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles.. Ann Neurol 1988 Jan;23(1):64-72.
- Paciello O, Shelton GD, Papparella S. Expression of major histocompatibility complex class I and class II antigens in canine masticatory muscle myositis.. Neuromuscul Disord 2007 Apr;17(4):313-20.
- Appleyard ST, Dunn MJ, Dubowitz V, Rose ML. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders.. Lancet 1985 Feb 16;1(8425):361-3.
- McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases.. J Neurol Sci 1989 Feb;89(2-3):213-26.
- Hohlfield R. Immune mechanisms in muscle diseases. Myology: Basic and Clinical 3rd ed New York: McGraw‐Hill, Medical Publishing Division; 2004:889–914.
- Yin X, Wang Q, Chen T, Niu J, Ban R, Liu J, Mao Y, Pu C. CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.. Int J Clin Exp Pathol 2015;8(3):3069-75.
- Cumming WJK. Color Atlas of Muscle Pathology. 1st ed London; Baltimore: Mosby‐Wolfe; 1994.
- Liu LA, Engvall E. Sarcoglycan isoforms in skeletal muscle.. J Biol Chem 1999 Dec 31;274(53):38171-6.
- Guo LT, Moore SA, Forcales S, Engvall E, Shelton GD. Evaluation of commercial dysferlin antibodies on canine, mouse and human skeletal muscle.. Neuromuscul Disord 2010 Dec;20(12):820-5.
- Shelton GD. From dog to man: the broad spectrum of inflammatory myopathies.. Neuromuscul Disord 2007 Oct;17(9-10):663-70.
- Morita T, Shimada A, Yashiro S, Takeuchi T, Hikasa Y, Okamoto Y, Mabuchi Y. Myofiber expression of class I major histocompatibility complex accompanied by CD8+ T-cell-associated myofiber injury in a case of canine polymyositis.. Vet Pathol 2002 Jul;39(4):512-5.
- Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, Tonali P. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies.. Clin Exp Immunol 1994 Jan;95(1):166-72.
- Shelton GD, Hoffman EP, Ghimbovschi S, Peters IR, Day MJ, Mullins M, Moore PF, Nagaraju K. Immunopathogenic pathways in canine inflammatory myopathies resemble human myositis.. Vet Immunol Immunopathol 2006 Sep 15;113(1-2):200-14.
- Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment.. Trends Immunol 2005 Jul;26(7):373-80.
- Jain A, Sharma MC, Sarkar C, Bhatia R, Singh S, Handa R. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies.. Arch Pathol Lab Med 2007 Jul;131(7):1070-6.
- McCue ME, Armién AG, Lucio M, Mickelson JR, Valberg SJ. Comparative skeletal muscle histopathologic and ultrastructural features in two forms of polysaccharide storage myopathy in horses.. Vet Pathol 2009 Nov;46(6):1281-91.
- Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies.. J Neuropathol Exp Neurol 1996 Mar;55(3):342-7.
- Dalakas MC. Immunopathogenesis of inflammatory myopathies.. Ann Neurol 1995 May;37 Suppl 1:S74-86.
- Dalakas MC. Review: An update on inflammatory and autoimmune myopathies.. Neuropathol Appl Neurobiol 2011 Apr;37(3):226-42.
- Shinjo SK, Sallum AM, Silva CA, Marie SK. Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis.. Clinics (Sao Paulo) 2012 Aug;67(8):885-90.
Citations
This article has been cited 6 times.- Ochala J, Finno CJ, Valberg SJ. Myofibre Hyper-Contractility in Horses Expressing the Myosin Heavy Chain Myopathy Mutation, MYH1(E321G).. Cells 2021 Dec 6;10(12).
- Gianino GM, Valberg SJ, Perumbakkam S, Henry ML, Gardner K, Penedo C, Finno CJ. Prevalence of the E321G MYH1 variant for immune-mediated myositis and nonexertional rhabdomyolysis in performance subgroups of American Quarter Horses.. J Vet Intern Med 2019 Mar;33(2):897-901.
- Valberg SJ, Henry ML, Perumbakkam S, Gardner KL, Finno CJ. An E321G MYH1 mutation is strongly associated with nonexertional rhabdomyolysis in Quarter Horses.. J Vet Intern Med 2018 Sep;32(5):1718-1725.
- Finno CJ, Gianino G, Perumbakkam S, Williams ZJ, Bordbari MH, Gardner KL, Burns E, Peng S, Durward-Akhurst SA, Valberg SJ. A missense mutation in MYH1 is associated with susceptibility to immune-mediated myositis in Quarter Horses.. Skelet Muscle 2018 Mar 6;8(1):7.
- Boyle AG, Timoney JF, Newton JR, Hines MT, Waller AS, Buchanan BR. Streptococcus equi Infections in Horses: Guidelines for Treatment, Control, and Prevention of Strangles-Revised Consensus Statement.. J Vet Intern Med 2018 Mar;32(2):633-647.
- Hunyadi L, Sundman EA, Kass PH, Williams DC, Aleman M. Clinical Implications and Hospital Outcome of Immune-Mediated Myositis in Horses.. J Vet Intern Med 2017 Jan;31(1):170-175.